Behavioral activation

Curio Digital Therapeutics Inc. Announces the U.S. Food and Drug Administration (FDA) Clearance of MamaLift Plus™, the First Prescription Digital Therapeutic Authorized for the Treatment of Postpartum Depression (PPD)

Retrieved on: 
Tuesday, April 23, 2024
Mental Health, Women, FDA, Baby, Maternity, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, American College, Regulation, PPD, Woman, Behavioral activation, Food, Cognitive behavioral therapy, BAT, Depression, DBT, Smartphone, Summer, ACOG, Therapy, Edinburgh Postnatal Depression Scale, Patient, MPH, Postpartum depression, Face, ITT, IPT, RCT, Dialectical behavior therapy, CBT, EPDS

Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.

Key Points: 
  • Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM.
  • MamaLift Plus treats mild to moderate postpartum depression by improving a patient’s symptoms of depression.
  • MamaLift Plus delivers digital Cognitive Behavioral Therapy (CBT), Behavioral Activation Therapy (BAT), Interpersonal Therapy (IPT), and Dialectical Behavior Therapy (DBT) for postpartum depression.
  • The clearance of MamaLift Plus is based on results from the Supporting Maternal Mental Health and Emotional Regulation (SuMMER).

Limbix Partners with the Children's Hospital Los Angeles to Study SparkRx

Retrieved on: 
Tuesday, September 6, 2022
Cardiology, Partnership, COVID-19, Research, Diathesis–stress model, Division, Children's Hospital Los Angeles, Smartphone, Gastroenterology, Ageing, CBT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, Comfort, Doctor of Philosophy, PTSD, Behavior, Suicide, Cognitive behavioral therapy, Palliative care, Food, Department, Grammatical mood, Principal, Adolescence, Reading, Depression, CHLA, Behavioral activation, Anesthesiology, Patient, Lists of diseases, Degenerative disease, FDA, Therapy, Population, Arousal, Mental health, Language isolate, Self-harm, Risk, Suicidal ideation, Pharmaceutical industry, Hospital, Residential care

SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Limbix is excited to announce a partnership with Children's Hospital Los Angeles (CHLA) for a research study to evaluate SparkRx , an adjunct treatment for adolescents with symptoms of depression, in specialty medical care settings.

Key Points: 
  • SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Limbix is excited to announce a partnership with Children's Hospital Los Angeles (CHLA) for a research study to evaluate SparkRx , an adjunct treatment for adolescents with symptoms of depression, in specialty medical care settings.
  • SparkRx is a self-guided, cognitive behavioral therapy (CBT)-based digital therapeutic intervention for adolescents, aged 13-22 years old.
  • "We are especially excited to partner with Children's Hospital Los Angeles to run this research study in specialty care settings to better understand the mental health needs of this patient population."
  • Through extensive research, Limbix built their first digital therapeutic, SparkRx, that delivers CBT-based treatment directly to each user's smartphone.

Limbix launches the Limbix Synapse platform to enable the development of robust and secure digital therapeutics

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Depression, CEO, Mental health, Technology, Adolescence, Suicide, Smartphone, Research, Compliance, Patient, Therapy, COVID-19, Diathesis–stress model, Self-harm, Partnership, Reading, Lists of diseases, Language isolate, Cognitive behavioral therapy, Arousal, PTSD, Food, Suicidal ideation, Behavioral activation, Mobile phone, Pharmaceutical industry, Hospital, Residential care

Through the platform, Limbix is able to efficiently build, distribute, and commercialize secure, compliant, and privacy-aware digital therapeutics.

Key Points: 
  • Through the platform, Limbix is able to efficiently build, distribute, and commercialize secure, compliant, and privacy-aware digital therapeutics.
  • With the Limbix Synapse platform, Limbix is able to quickly build, test, and monitor clinical-grade therapeutics through the platform's mobile therapeutic development system, ensuring their security and compliance.
  • The highly scalable Limbix Synapse platform enables the simultaneous development and deployment of multiple therapeutics, including Limbix's first digital therapeutic, SparkRx.
  • The development and commercialization of SparkRx is conducted through the Limbix Synapse platform which enables the development and clinical research of secure, compliant, and privacy aware digital therapeutics.

Limbix Launches First Digital Therapeutic for Adolescents with Symptoms of Depression

Retrieved on: 
Friday, October 8, 2021
Other Health, Software, Mobile, Wireless, Family, Consumer, Mental Health, Technology, Teens, Parenting, Children, Clinical Trials, Health, Mindfulness, Mental health, Pediatrics, Cognitive behavioral therapy, Behavior, Adolescence, Conference, COVID-19, Food, Program, Safety, Smartphone, FDA, Depression, Problem solving, Behavioral activation, Grammatical mood, American Academy, Therapy, Ageing, Policy, Patient, Clinical trial, Psychology, Pharmaceutical industry, Toy, Medicine, SparkRx, Limbix, SPARKRX, LIMBIX

Today, Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, announced the launch of SparkRx , the first evidence-based digital therapeutic for teens and young adults experiencing symptoms of depression.

Key Points: 
  • Today, Limbix , a prescription digital therapeutic company developing mental health treatments for adolescents, announced the launch of SparkRx , the first evidence-based digital therapeutic for teens and young adults experiencing symptoms of depression.
  • Limbix SparkRx is a cognitive behavioral therapy-based digital therapeutic program for teens and young adults experiencing symptoms of depression.
  • Limbix is a prescription digital therapeutic company passionate about creating mental health treatments for adolescents.
  • Their first digital therapeutic, Limbix SparkRx, is now available for licensed health care professionals to offer to patients nationwide.